Relmada Therapeutics, Inc. RLMD
4.27 USD +0.13 (+3.14%)
At closeNov 10, 2026, 4:01 PM EST
4.27 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
4.11 Day range 4.31
2.97 52-week range 8.00
- YTD
- -11.59%
- 1 year
- +41.86%
News
globenewswire.com Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
globenewswire.com Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
benzinga.com Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call Relmada Therapeutics (NASDAQ:RLMD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
benzinga.com Alpha Buying: 4 Biotech Stocks Insiders Are Betting On I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity…
defenseworld.net Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00 Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Evogene (NASDAQ:EVGN) shares increased by 75.0% to $0.72 during Tuesday's after-market session. The company's market cap stands at $4.5 million. AIxCrypto Hldgs (NASDAQ:AIXC) stock moved…
defenseworld.net 812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE Bank of America Corp DE acquired a new stake in Relmada Therapeutics, Inc. (NASDAQ: RLMD) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
zacks.com 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX)…
globenewswire.com Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
zacks.com After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts…
zacks.com Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong…
zacks.com Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
marketbeat.com Relmada Therapeutics Q2 Earnings Call Highlights Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive…
seekingalpha.com Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
benzinga.com Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 63.33 percent increase over losses of…
defenseworld.net Critical Review: Relmada Therapeutics (NASDAQ:RLMD) versus Novo Nordisk A/S (NYSE:NVO) Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
defenseworld.net ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics, Inc. (NASDAQ: RLMD) by 1,364.1% in the undefined quarter, according to its most recent disclosure with the SEC. The firm…
globenewswire.com Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
defenseworld.net Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short Interest Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 10,647,441 shares, a…
globenewswire.com Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
benzinga.com Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today
globenewswire.com Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
benzinga.com Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a primary focus on bladder cancer treatment regimen.
benzinga.com Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
benzinga.com This Talen Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Check out analysts' views on TRNO, RLMD, TLN, IMMX, CEG.
benzinga.com HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $12.
globenewswire.com Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
benzinga.com Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock jumped 11.73%.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Hewlett Packard Enterprise Posts Blowout Q2 Earnings, Joins Marvell Technology And Other Big Stocks Moving Higher In Tuesday's Session US stock futures surge on tech sector news, HPE reports strong earnings, and other tech stocks follow suit in pre-market trading.- benzinga.com Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval On May 28, 2026, Relmada Therapeutics, Inc. (the "Company") filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number…
globenewswire.com Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for…
benzinga.com Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed RELMADA THERAPEUTICS, INC.COMMON STOCKPREFERRED STOCKWARRANTSSUBSCRIPTION RIGHTSDEPOSITARY SHARESPURCHASE CONTRACTSUNITSThis prospectus relates to common stock, preferred stock, warrants,…- benzinga.com Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call
- benzinga.com Relmada Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 62.07 percent increase over losses of…
benzinga.com Earnings Scheduled For May 12, 2026 
benzinga.com Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12 Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Overweight rating and announces Price Target of $12.
benzinga.com Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19 Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.- benzinga.com Relmada Therapeutics Q4 EPS $(0.27) Misses $(0.14) Estimate Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.14) by 92.86 percent. This is a 56.45 percent increase over losses…
- benzinga.com Earnings Scheduled For March 19, 2026
benzinga.com FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving lower in pre-market trading.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
benzinga.com Why Is Relmada Therapeutics Stock Soaring Monday? Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Market-Moving News for March 9th HIMS: 54% | Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report RLMD: 80% | Relmada Therapeutics Announces 12-month Interim Data From Its- benzinga.com Relmada Therapeutics Announces Private Placement Of $160M Pursuant to the terms of the securities purchase agreement, Relmada is selling an aggregate of (i) 29,474,569 shares of its common stock ("Common Stock") at a purchase price of $4.75 per share and…
- benzinga.com Relmada Therapeutics Announces 12-month Interim Data From Its Ongoing Phase 2 Trial Of NDV-01 For High-risk Non-muscle Invasive Bladder Cancer Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any…
benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14 LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $14.